e7080

Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.

Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.

O-Demethyl Lenvatinib, a metabolite of Lenvatinib (E7080), is an orally administered, multi-targeted tyrosine kinase inhibitor. It effectively inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, demonstrating significant antitumor activities [1] [2].

O-Demethyl Lenvatinib hydrochloride, a metabolite of Lenvatinib (E7080), is an orally administered multi-targeted tyrosine kinase inhibitor. It targets and inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, demonstrating potent antitumor activities [1] [2].

Lenvatinib (Standard) is a reference standard for research and analysis in studies involving Lenvatinib. Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.